Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

TLR4 antagonists for endotoxemia and beyond.

Daniel P Rossignol1, Melvyn Lynn

  • 1Eisai Medical Research Inc, NJ 07660, USA. dan_rossignol@eisai.com

Current Opinion in Investigational Drugs (London, England : 2000)
|May 26, 2005
PubMed
Summary

Toll-like receptor 4 (TLR4) detects pathogens but can cause harmful inflammation. Research explores TLR4 antagonists like eritoran to treat diseases linked to TLR4 overstimulation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The TLR4 antagonist Eritoran protects mice from lethal influenza infection.

Nature·2013
Same author

Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.

JAMA·2013
Same author

Safety, pharmacokinetics and pharmacodynamics of four-hour intravenous infusions of eritoran in healthy Japanese and Caucasian men.

Innate immunity·2012
Same author

Influence of severity of illness on the effects of eritoran tetrasodium (E5564) and on other therapies for severe sepsis.

Shock (Augusta, Ga.)·2011
Same author

Deactivation of the lipopolysaccharide antagonist eritoran (E5564) by high-density lipoprotein-associated apolipoproteins.

Innate immunity·2011
Same author

Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies.

Clinical cancer research : an official journal of the American Association for Cancer Research·2011

Area of Science:

  • Immunology
  • Pathogen detection
  • Inflammatory response

Background:

  • Toll-like receptor 4 (TLR4) is crucial for detecting Gram-negative bacterial endotoxins.
  • TLR4 activation normally triggers an antibacterial immune response.
  • Dysregulated TLR4 signaling can lead to severe systemic inflammation and organ failure.

Purpose of the Study:

  • To review research on TLR4 antagonists for treating diseases.
  • To discuss the potential of eritoran (E-5564) and other TLR4 inhibitors.
  • To explore TLR4's role in various pathological conditions.

Main Methods:

  • Review of current preclinical and clinical research.
  • Focus on eritoran (E-5564), a lipid A analog.
  • Examination of other TLR4 antagonists.

Main Results:

  • TLR4 responds to both pathogen-derived and endogenous ligands.
  • Overstimulation of TLR4 can cause life-threatening systemic inflammation.
  • Eritoran and other antagonists show therapeutic potential.

Conclusions:

  • TLR4 antagonists represent a promising therapeutic strategy.
  • Targeting TLR4 may mitigate inflammatory diseases.
  • Further research is needed to fully elucidate therapeutic applications.

Related Experiment Videos